Neogen Corporation logo

Neogen Corporation(NEOG)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
5-STAR RATING
PASS
LAST CLOSE
$11.08
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NEOG

11/18/2026: NEOG (5-star) is currently NOT-A-BUY. Pass it for now.

Neogen Corporation is a specialized healthcare and diagnostics stock operating primarily in the global food and animal safety sectors. The company's core strengths stem from its trusted diagnostic test kits and the transformative integration of the 3M food safety business, which underpins its leading market position. Its primary growth opportunity lies in expanding high-margin product innovations and capturing increasing international food compliance demand. However, investors must weigh execution risks associated with large-scale integration and intense competition from larger life science conglomerates. The stock suits growth-oriented investors willing to navigate intermediate volatility while monitoring ongoing margin expansion and operational milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitNeogen offers structural growth drivers in food safety testing, though near-term organic growth rates are moderated by ongoing portfolio transitions.
Momentum investorStrong fit while signal remains positivePositive earnings surprises and upward guidance revisions can trigger sharp upward momentum phases.
Value investorMixed fitValuation multiples reflect multi-year turnaround and integration expectations rather than bargain-level pricing.
Dividend investorWeak fitNeogen does not pay dividends, prioritizing capital reinvestment and debt reduction instead.
Low-risk investorWeak fitExecution risks related to major business integration and post-merger adjustments create notable stock volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock frequently reacts sharply to quarterly execution updates and margin progress reports.
Valuation riskMediumMarket pricing heavily relies on the successful realization of long-term margin expansion goals.
Competition risk (name the main competitor theme, e.g. AI competition)Medium / highAggressive competition from global life science and diagnostics giants can pressure market share and pricing power.
Business qualityMediumThe core franchise enjoys sticky customer relationships in food safety, though historical earnings consistency has been impacted by integration overhead.
Dividend incomeLow / noneIncome-focused investors receive no cash return from dividends.
Execution riskHighSuccessfully integrating large operations like the 3M food safety unit requires flawless operational management.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.38B USD
Price to earnings Ratio -
1Y Target Price 14
Price to earnings Ratio -
1Y Target Price 14
Volume (30-day avg) 3.1M shares
Beta 1.86
52 Weeks Range 5.37 - 14.26
Updated Date 11/18/2026
52 Weeks Range 5.37 - 14.26
Updated Date 11/18/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.26

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.0%
Active BUY / eligible
67 / 108
30-Day BUY Count Change
+22
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
50.0%
Active BUY / eligible
4 / 8
30-Day BUY Count Change
+2

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 71.18%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NEOG receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
NEOG has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2026 versus FY2025, strong earnings growth (+99.3%) is partially offset by soft cash generation (FCF margin 3.7%), slightly negative revenue growth (-2.7%), weak profitability (net margin -0.9%).

Financial Health Rating

★★★★★
NEOG's financial health is supported by moderate cash strength, including free-cash-flow generation (3.7% of revenue). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is NEOG's strongest growth driver at +168.8% FY2026 versus FY2025 (strong, 5 stars). By comparison, earnings growth (+99.3%, strong) is also strong, while revenue growth (-2.7%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 110.2% and approximately 99.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.79%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 15.31%
Neuberger Berman Group LLC 7.59%
Vanguard Portfolio Management, LLC 5.97%
Dimensional Fund Advisors, Inc. 4.71%
Vanguard Capital Management, LLC 4.42%

Unit Economics (Per $1K Revenue)

★★★★★
NEOG generates approximately $469 of gross profit, $-25 of operating income, and $37 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 12.22%

Quantitative Style Profile

★★★★★
NEOG has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Food SafetyDiagnostic kits, pathogen tests, allergen detection systems, and sanitation monitoring tools sold to food processors.This is the core engine providing sticky recurring revenue from industrial food quality control.
Animal SafetyVeterinary pharmaceuticals, biosecurity disinfectants, insecticides, and agricultural genomics services.Provides stable diversification across livestock management and veterinary care end-markets.
International OperationsDirect sales and distribution networks spanning the Americas, EMEA, and Asia-Pacific regions.Offers geographic diversification but introduces foreign currency translation exposure.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 16
Enterprise Value 2.98B
Price to Sales(TTM) 2.69
Enterprise Value 2.98B
Price to Sales(TTM) 2.69
Enterprise Value to Revenue 3.37
Enterprise Value to EBITDA 27.07
Shares Outstanding 218.31M
Shares Floating 217.24M
Shares Outstanding 218.31M
Shares Floating 217.24M
Percent Insiders 0.79
Percent Institutions 110.24

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.